Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Aicuris Gmbh + Co. Kg.

Other

Bayer Schering Pharma Ag

Bayer Healthcare Aktiengesellschaft

Bayer Pharmaceuticals Corporation

Bayer Aktiengeselischaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Marcus Bauser

Hartmut Rehwinkel

Stefan Heitmeier

Roland Neuhaus

Dieter Lang

Christoph Gerdes

Duy Nguyen

Mark Jean Gnoth

Karl-Heinz Schlemmer

Adrian Tersteegen

Sven Ring

Johannes-Peter Stasch

Elisabeth Perzborn

Thomas Schenke

Katja Zimmermann

Wolfgang Schwede

Rudolf Schohe-Loop

Ulrich Rosentreter

Klaus Dembowsky

Susanne Röhrig

Walter Hübsch

Andrea Vaupel

Kerstin Henninger

Hartmut Schirok

Thomas Krahn

Philip Lienau

Volkhart Min-Jian Li

Wahed Ahmed Moradi

Jörg Keldenich

Knut Eis

Nils Griebenow

Martin Hendrix

Josef Pernerstorfer

Kai Thede

Achim Feurer

Tobias Wunberg

Heike Heckroth

Paul Naab

Arnold Paessens

Anja Buchmüller

Raimund Kast

Axel Kretschmer

Elke Stahl

Ulrich Rester

Swen Allerheiligen

Sonja Anlauf

Olaf Panknin

Stefan Kaulfuss

Elke Dittrich-Wengenroth

Holger Siebeneicher

Georges Von Degenfeld

Michael Härter

Leila Telan

Nils Burkhardt

Jens-Kerim Ergüden

Dietmar Flubacher

Barbara Albrecht

Rolf Henning

Daniela Paulsen

Thomas Krämer

Dirk Heimbach

Maria Niewöhner

Jürgen Stoltefuss

Detlev Sülzle

Siegfried Zaiss

Jens Ackerstaff

Claudia Hirth-Dietrich

Friederike Stoll

Johannes Köbberling

Philipp Buchgraber

Hartmut Beck

Holger Zimmermann

Olaf Weber

Ningshu Liu

Stefan Golz

Simon Holton

Chantal Fuerstner

Frank Süβmeier

Klaus Münter

Niels Svenstrup

Holger Paulsen

Ulf Brüggemeier

Heike Gielen-Haertwig

Stephan Siegel

Thomas Roelle

Stephen Boyer

Mark Meininghaus

Frank Dittmer

Arno Friedl

Reinhard Jork

Joachim Krüger

Elisabeth Woltering

Eckhard Bender

Volkhart Li

Johannes Koebberling

József Bálint

Dagmar Schauss

David Brueckner

Franziska Siegel

Julia Straβburger

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Benzimidazol-2-amines as mIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I) in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors

Benzimidazol-2-amines as MIDH1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to benzimidazol-2-amines of general formula (I): in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to amido-substituted azole compounds of general formula (I), in which X, X, R, R, R, R, Rand Rare as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Amido-substituted azole compounds

The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Substituted oxazolidinones and their use

The present invention relates to novel substituted pyrazolamides, methods for their preparation, their use for the treatment and/or prophylaxis of diseases, as well as their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of retroviral diseases, in humans and/or animals.

Substituted pyrazolamides and their use

The invention relates to aryl-substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Aryl-substituted heterocycles, and use thereof

The invention relates to novel substituted oxazolidinones, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases, and to the use thereof for producing medicaments for treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.

The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

Dihydropyridinone derivatives

The invention relates to substituted quinolones and to processes for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.

Substituted quinolones

The invention relates to substituted [(phenylethanoyl)amino]benzamides and methods for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of inflammatory disorders such as, for example, cutaneous, respiratory tract and cardiovascular disorders such as, for example, arteriosclerosis and coronary heart disease.

Substituted [(phenylethanoyl)amino]benzamides

Growing community of inventors

Berlin, Germany

Marcus Bauser